KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash & Current Investments: 2014-2024

Historic Cash & Current Investments for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to $2.6 billion.

  • BeOne Medicines' Cash & Current Investments rose 49.41% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 billion, marking a year-over-year increase of 5.99%. This contributed to the annual value of $2.6 billion for FY2024, which is 17.23% down from last year.
  • BeOne Medicines' Cash & Current Investments amounted to $2.6 billion in FY2024, which was down 17.23% from $3.2 billion recorded in FY2023.
  • Over the past 5 years, BeOne Medicines' Cash & Current Investments peaked at $6.6 billion during FY2021, and registered a low of $2.6 billion during FY2024.
  • Over the past 3 years, BeOne Medicines' median Cash & Current Investments value was $3.2 billion (recorded in 2023), while the average stood at $3.4 billion.
  • In the last 5 years, BeOne Medicines' Cash & Current Investments surged by 373.24% in 2020 and then crashed by 31.47% in 2022.
  • BeOne Medicines' Cash & Current Investments (Yearly) stood at $4.7 billion in 2020, then spiked by 42.29% to $6.6 billion in 2021, then tumbled by 31.47% to $4.5 billion in 2022, then decreased by 30.00% to $3.2 billion in 2023, then decreased by 17.23% to $2.6 billion in 2024.